SCHEMBL12486972

SCHEMBL12486972

O=C(O)N[C@H](C(=O)N1CC[C@H](O)C1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 7/20 0.44
F2 P00734 4/20 0.44
PRSS1 P07477 4/20 0.44
KCNA3 P22001 1/20 0.41
CXCR1 P25024 1/20 0.41
CXCR2 P25025 1/20 0.41
GRM5 P41594 1/20 0.41
CYP2D6 P10635 3/20 0.41
OPRK1 P41145 2/20 0.41
KLRK1 P26718 1/20 0.40
MICA Q29983 1/20 0.40
CYP3A4 P08684 2/20 0.40
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
KCNH2 Q12809 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MTTP P55157 1/20 0.39
DPP4 P27487 1/20 0.39
DPP7 Q9UHL4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16973973 1.00 F10 (0.44) F10F2PRSS1KCNA3CXCR1
SCHEMBL17764976 1.00 F10 (0.44) F10F2PRSS1KCNA3CXCR1
SCHEMBL27978387 1.00 F10 (0.44) F10F2PRSS1KCNA3CXCR1
SCHEMBL21315830 1.00 F10 (0.44) F10F2PRSS1KCNA3CXCR1
SCHEMBL29395657 0.87 KCNH2 (0.51) F10F2PRSS1CYP2D6OPRK1
SCHEMBL21575680 0.86 CYP2D6 (0.44) F10KCNA3CXCR1CXCR2CYP2D6
SCHEMBL18368294 0.85 KDM4E (0.48) F10F2PRSS1CYP2D6OPRK1
SCHEMBL17883715 0.83 CTSS (0.49) F10F2PRSS1CYP2D6CYP3A4
SCHEMBL16419148 0.82 CTSK (0.52) F10F2PRSS1CYP2D6OPRK1
SCHEMBL10084036 0.82 CTSK (0.52) F10F2PRSS1CYP2D6OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104133010-B High performance liquid chromatography separation analysis Asimadoline intermediate and optical isomer 北京万全德众医药生物技术有限公司 2019-11-29 CN disclosed
US-10131655-B2 Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists DR. REDDY'S LABORATORIES, LTD. (IN) 2018-11-20 US disclosed
EP-2822928-B1 SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS Dr Reddys Laboratories Ltd (IN) 2018-11-14 EP disclosed
US-20170001998-A1 SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS DR. REDDY'S LABORATORIES, LTD. (IN) 2017-01-05 US disclosed
EP-3097093-A1 NOVEL HETEROBICYCLIC COMPOUNDS AS KAPPA OPIOID AGONISTS Cadila Healthcare Limited (IN) 2016-11-30 EP disclosed
US-9487510-B2 Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists DR. REDDY'S LABORATORIES LTD. (IN) 2016-11-08 US disclosed
US-9303027-B2 Kappa opioid receptor agonists DR. REDDY'S LABORATORIES LTD. (IN) 2016-04-05 US disclosed
WO-2015114660-A1 NOVEL HETEROBICYCLIC COMPOUNDS AS KAPPA OPIOID AGONISTS CADILA HEALTCHARE LIMITED (IN) 2015-08-06 WO disclosed
EP-2822928-A1 SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS Dr. Reddy's Laboratories Ltd. (IN) 2015-01-14 EP disclosed
CN-104133010-A Method for separating and analyzing asimadoline intermediate and optical isomers by using HPLC BEIJING VENTUREPHARM BIOTECH CORP 2014-11-05 CN disclosed
CN-104133010-A Method for separating and analyzing asimadoline intermediate and optical isomers by using HPLC BEIJING VENTUREPHARM BIOTECH CORP 2014-11-05 CN disclosed
US-20130303525-A1 KAPPA OPIOID RECEPTOR AGONISTS DR. REDDY'S LABORATORIES, INC. (US) 2013-11-14 US disclosed
WO-2013131408-A1 SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS DR.REDDY'S LABORATORIES LTD. (IN) 2013-09-12 WO disclosed
WO-2012012410-A2 KAPPA OPIOID RECEPTOR AGONISTS DR. REDDY'S LABORATORIES LTD. (IN) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170001998-A1 SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS OPRK1, OPRL1, OPRD1 F10 2769/4885F2 2834/4885PRSS1 2125/4885
US-20130303525-A1 KAPPA OPIOID RECEPTOR AGONISTS OPRK1, OPRL1, OPRD1 F10 2457/4885F2 2008/4885PRSS1 1119/4885
US-10131655-B2 Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists OPRK1, OPRL1, OPRD1 F10 2769/4885F2 2834/4885PRSS1 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.